Of course I'd want a DurAVR. I hope people don't think I'm criticizing the performance of the DurAVR and I have 10k shares, which is one of the larger positions in my individual stock portfolio, so I'm very invested in the company's future.
I'm just giving what I think is a realistic view of our chances to get a humanitarian exception based on my experience. When it comes to the company's financial future, I'm very bullish as I've pointed out in my posts. When it comes to Wayne's timelines and potential FDA shortcuts, I'm skeptical based on what I've learned about the FDA in my years of investing in clinical-stage companies.
But, as I've said, I'm not the utmost expert on these things so there's a chance I could be wrong.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)